RSS-Feed abonnieren
DOI: 10.1055/s-0034-1377306
Somatostatin for prevention of post-ERCP pancreatitis: a randomized, double-blind trial
Publikationsverlauf
submitted 05. November 2013
accepted after revision 08. April 2014
Publikationsdatum:
30. Juni 2014 (online)
![](https://www.thieme-connect.de/media/endoscopy/201410/lookinside/thumbnails/10.1055-s-0034-1377306-1.jpg)
Background and study aims: Meta-analyses suggest that an intravenous bolus or a high dose continuous infusion of somatostatin reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). Clinical guidelines, however, do not recommend this prophylaxis. The aim of this randomized, double-blind clinical trial was to evaluate the effect of somatostatin on the incidence of post-ERCP pancreatitis.
Patients and methods: Patients undergoing ERCP at a single center were randomized to either intravenous bolus of somatostatin followed by a short (4-hour) continuous infusion, or to a similar placebo regimen. The primary outcome was post-ERCP pancreatitis, defined as abdominal pain with an amylase level at least three times higher than the upper limit of normality 24 hours after the ERCP and requiring admission for at least 2 days.
Results: A total of 510 patients were enrolled (255 patients per group) and all completed follow-up. The main indications for ERCP were choledocholithiasis (62 %), and biliary malignant stricture (31 %). Post-ERCP pancreatitis occurred in 19 patients (7.5 %) in the somatostatin group and 17 patients (6.7 %) in the placebo group (relative risk [RR] 1.12, 95 % confidence interval [95 %CI] 0.59 – 2.1; P = 0.73). The number of cases of moderate or severe acute pancreatitis was similar in the somatostatin (2.4 %) and the placebo (3.5 %) groups (RR 0.67, 95 %CI 0.24 – 1.85, P = 0.43). No side effects were observed related to the use of somatostatin.
Conclusions: Administration of an intravenous bolus of somatostatin followed by a short continuous infusion does not reduce the incidence of post-ERCP pancreatitis.
Clinical Trials.gov number: NCT01060826.
-
References
- 1 Dumonceau JM, Andriulli A, Deviere J et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 2010; 42: 503-515
- 2 Anderson MA, Fisher L, Jain R. ASGE Standards of Practice Committee et al. Complications of ERCP. Gastrointest Endosc 2012; 75: 467-473
- 3 Arata S, Takada T, Hirata K et al. Post-ERCP pancreatitis. J Hepatobiliary Pancreat Sci 2010; 17: 70-78
- 4 Dollinger HC, Raptis S, Pfeiffer EF. Effects of somatostatin on exocrine and endocrine pancreatic function stimulated by intestinal hormones in man. Horm Metab Res 1976; 8: 74-78
- 5 Gullo L, Priori P, Scarpignato C et al. Effect of somatostatin 14 on pure human pancreatic secretion. Dig Dis Sci 1987; 32: 1065-1070
- 6 Lai KH, Lo GH, Cheng JS et al. Effect of somatostatin on the sphincter of Oddi in patients with acute non-biliary pancreatitis. Gut 2001; 49: 843-846
- 7 Binmoeller KF, Dumas R, Harris AG et al. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992; 37: 773-777
- 8 Karalis K, Mastorakos G, Chrousos GP et al. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93: 2000-2006
- 9 Yuan Y, Gong Z, Lou K et al. Effects and mechanisms of somatostatin analogs on apoptosis of pancreatic acinar cells in acute pancreatitis in mice. J Gastroenterol Hepatol 2001; 16: 683-688
- 10 Bordas JM, Toledo-Pimentel V, Llach J et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998; 47: 230-234
- 11 Poon RT, Yeung C, Lo CM et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49: 593-598
- 12 Andriulli A, Clemente R, Solmi L et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56: 488-495
- 13 Poon RT, Yeung C, Liu CL et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 2003; 52: 1768-1773
- 14 Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas 2008; 37: 445-448
- 15 Andriulli A, Leandro G, Niro G et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51: 1-7
- 16 Andriulli A, Leandro G, Federici T et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65: 624-632
- 17 Rudin D, Kiss A, Wetz RV et al. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol 2007; 22: 977-983
- 18 Omata F, Deshpande G, Tokuda Y et al. Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol 2010; 45: 885-895
- 19 Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393
- 20 Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
- 21 Elmunzer BJ, Waljee AK, Elta GH et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-1267
- 22 Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8: 11-16
- 23 Ding X, Chen M, Huang S et al. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc 2012; 76: 1152-1159
- 24 Yuhara H, Ogawa M, Kawaguchi Y et al. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol 2014; 49: 388-399 (Epub 2013 May 30)
- 25 Singh P, Das A, Isenberg G et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60: 544-550
- 26 Andriulli A, Forlano R, Napolitano G et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007; 75: 156-163
- 27 Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy 2010; 42: 842-853
- 28 Choudhary A, Bechtold ML, Arif M et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73: 275-282
- 29 Mazaki T, Mado K, Masuda H et al. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. J Gastroenterol 2014; 49: 343-355
- 30 Das A, Singh P, Sivak Jr MV et al. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc 2007; 65: 960-968